PA-BOOMI
11.6.2024 18:01:29 CEST | Business Wire | Press release
Boomi™, the intelligent integration and automation leader, today announced that the six inaugural Boomi AI Agents recently unveiled at the company’s Boomi World event will be available in the Boomi Enterprise Platform as part of existing customer licenses, enabling customers to fully harness AI-powered capabilities for unparalleled innovation. These agents include:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611275117/en/
Boomi Announces New AI Agents Available on the Boomi Enterprise Platform, Enabling Unmatched Speed for Innovation (Graphic: Business Wire)
- Boomi Answers: Save time spent searching through user community discussions and articles. Simply ask questions about Boomi and get the most useful answer from over 240K community users.
- Boomi DataDetective: Stay on top of data privacy, protect sensitive information with AI-powered data classification, and track where data is being moved.
- Boomi DesignGen: Ask GenAI to design integration processes based on 200M+ common patterns and best practices.
- Boomi GPT: Describe integration and automation needs using natural language and have conversations with the Boomi Enterprise Platform to get more meaningful results, faster.
- Boomi Pathfinder: Provide patented suggestions on the next best steps to take when building integration processes.
- Boomi Scribe: Skip manually writing documentation about existing and AI-generated integration processes, and let GenAI handle the busywork of detailing process descriptions and business use cases.
To accelerate innovation, Boomi recently introduced the Boomi AI Agent Framework, a set of integration and no-code development capabilities that enable business and IT users to run AI agents built by Boomi or Boomi partners, and to build and run their own AI agents to solve pressing integration and automation requirements.
“AI agents are revolutionizing industries by automating repetitive tasks, analyzing vast datasets, and offering personalized customer service,” said Steve Lucas, CEO at Boomi. “Data is the lifeblood of AI, especially with pre-trained transformers and LLM's. Boomi delivers that data, and the Boomi AI Agents improve efficiency, accuracy, and scalability for organizations by operating around the clock with high precision, enhancing decision-making, supporting human workers, and driving innovation. These capabilities lead to increased productivity and cost savings, making them invaluable assets for organizations to maintain a competitive edge."
AI agents are sophisticated software entities designed with a specific scope and personality, enabling them to function within predefined parameters and exhibit particular behaviors. Operating autonomously, they can make decisions using advanced AI-based reasoning algorithms, and can independently take actions to achieve their objectives. AI agents can function with or without human intervention. Additionally, AI agents can either work independently or collaborate with other AI agents, depending on the requirements of the task at hand. This flexibility and autonomy make AI agents highly versatile and capable of performing a wide range of functions across various applications, improving decision-making processes with data-driven insights, and powering innovation by enabling new applications and services.
The Boomi AI Agent Framework includes three types of agents running on the Boomi Enterprise Platform:
Boomi AI Agents
Boomi AI Agents provide AI-powered capabilities within the platform. These capabilities can be utilized through the Boomi GPT conversational user interface (CUI), via specialized GUI, in the process canvas, or via API.
Partner AI Agents
Partner AI agents are pluggable components that allow Boomi Enterprise Platform users to install and use best-of-breed AI functions from Boomi’s network of partners. These agents can be utilized in the same way as Boomi AI Agents, and allow rich capabilities to be incorporated from across the digital ecosystem. An example is the recently announced Boomi FinTalk powered by Vianai agent that allows business users to get detailed responses on financial information via Boomi GPT.
User-created AI Agents
User-created AI agents are developed using the Boomi Enterprise Platform, which provides all the necessary building blocks. Boomi’s connectivity and orchestration capabilities enable users to interact with selected models via API, access proprietary data sources, and automate actions through various applications. The Boomi platform’s process canvas allows the creation of sophisticated workflows to retrieve, combine, filter, and contextualize data, facilitating model prompting and techniques like RAG and fine-tuning. Boomi DataHub serves as an access point and repository for the agents’ knowledge base, while Boomi Flow and Boomi API Management offer human or machine interfaces to package these components into standalone AI agents.
Boomi AI Agents will be available with the July 2024 release of the Boomi Enterprise Platform. More information can be found here.
Additional Resources
- Read up on the latest blog posts from the Boomi leadership team
- Explore the Boomiverse Community
- Follow Boomi on X (Twitter), LinkedIn, Facebook, and YouTube
About Boomi
Boomi powers the future of business with intelligent integration and automation. As a category-leading, global software as a service (SaaS) company, Boomi celebrates more than 20,000 global customers and a worldwide network of 800 partners. Organizations turn to Boomi’s award-winning platform to connect their applications, data, and people to accelerate digital transformation. For more information, visit boomi.com.
© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611275117/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
